Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 27, Issue 9, Pages 1193-1202
Publisher
Springer Nature
Online
2014-01-17
DOI
10.1038/modpathol.2013.226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ron Receptor Tyrosine Kinase Activation Confers Resistance to Tamoxifen in Breast Cancer Cell Lines
- (2015) Rebecca J. McClaine et al. NEOPLASIA
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Impact of MET expression on outcome in BRAFV600E/Kadvanced melanoma
- (2013) Adrian M Jubb et al. HISTOPATHOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-PD-1 approaches—important steps forward in metastatic melanoma
- (2013) Mina Razzak Nature Reviews Clinical Oncology
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
- (2012) Christine Guo Lian et al. CELL
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAP kinase signaling and inhibition in melanoma
- (2012) R J Sullivan et al. ONCOGENE
- Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells
- (2012) Marine Chartrain et al. PLoS One
- Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box
- (2011) Caterina Marchiò et al. BMC Medicine
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- SOX2 contributes to melanoma cell invasion
- (2011) Sasha D Girouard et al. LABORATORY INVESTIGATION
- Unpublished results hide the decline effect
- (2011) Jonathan Schooler NATURE
- Bring on the biomarkers
- (2011) George Poste NATURE
- Improved outcomes for patients with metastatic melanoma
- (2011) Vernon K. Sondak et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Negative results are disappearing from most disciplines and countries
- (2011) Daniele Fanelli SCIENTOMETRICS
- Before You Analyze a Human Specimen, Think Quality, Variability, and Bias
- (2010) Mark David Lim et al. ANALYTICAL CHEMISTRY
- Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
- (2010) U. McDermott et al. CANCER RESEARCH
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
- (2010) Daniele Fanelli PLoS One
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Validation of Analytic Methods for Biomarkers Used in Drug Development
- (2008) C. H. Chau et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Identification of cells initiating human melanomas
- (2008) Tobias Schatton et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started